Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) saidon Wednesday that its revenue for the first half of 2025 reached 15.76 billion yuan ($2.19 billion), up 15.9% year-on-year. Its…
Investors pile into CANbridge stock but can the rally last?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies…
XtalPi scores landmark deal for AI drug discovery
The biotech has partnered with U.S. firm DoveTree in a collaboration worth up to $5.99 billion, adding to a slew of major deals for Chinese research firms this year Key…
Ab&B fortifies for battle over China’s vaccine market
With proceeds from a Hong Kong IPO, the loss-making biotech is bidding for a piece of China’s fiercely competitive market for flu and human rabies vaccines Key Takeaways: The company’s…
BRIEF: WuXi AppTec raises $975 Million through share placement at 6.9% discount
Pharmaceutical outsourcing giant WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) announced on Thursday it will raise HK$7.65 billion ($975 million) by placing around 73.8 million new Hong Kong-listed shares at HK$104.27…
Rising profit at WuXi Biologics underscores drug sector rebound
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expects…
Recent Articles
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
BRIEF: Kelun-Biotech raises $250 million through share placement
6990.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
9939.HK
